The last few months have been eventful for cancer therapy company WntResearch. In August, the company announced unexpected and promising findings with the candidate Foxy-5 in the phase II study Neofox, which prompted the company to change its plans for the study. CEO Pernilla Sandwall told us more about the updated study strategy in connection with the BioStock Investor Meeting.

See the interview with WntResearch’s CEO Pernilla Sandwall below.